Market Research Logo

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.

Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infection with the Epstein-Barr virus (EBV) and HIV infection are at increased risk compared to the general population. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018 16Number of Products under Development by Companies, H2 2018 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018 16Number of Products under Development by Companies, H2 2018 The guide covers therapeutics under Development by Companies /Universities /Institutes,

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018 16Number of Products under Development by Companies, H2 2018

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018 16Number of Products under Development by Companies, H2 2018 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Overview
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Therapeutics Assessment
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Companies Involved in Therapeutics Development
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Drug Profiles
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AbbVie Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Actinium Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by ADC Therapeutics SA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Affimed GmbH, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AlfaSigma SpA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Alissa Pharma, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Amgen Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by AstraZeneca Plc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by BeiGene Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Bristol-Myers Squibb Co, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by CBT Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celgene Corp, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cell Medica Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celldex Therapeutics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectar Biosciences Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellectis SA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Celleron Therapeutics Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellestia Biotech AG, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Checkpoint Therapeutics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Chipscreen Biosciences Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Curis Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Eli Lilly and Co, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Faron Pharmaceuticals Oy, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by FLX Bio Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Immunomedics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Incyte Corp, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kiromic Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Kite Pharma Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by MedImmune LLC, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Merck KGaA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Miltenyi Biotec GmbH, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Mirati Therapeutics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Molecular Templates Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NantKwest Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by NBE-Therapeutics AG, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rafael Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rhizen Pharmaceuticals SA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Rich Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Seattle Genetics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Selvita SA, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Syndax Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TaiGen Biotechnology Co Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by TRACON Pharmaceuticals Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline by Trillium Therapeutics Inc, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report